1
|
Mussetti A, Rius-Sansalvador B, Moreno V, Peczynski C, Polge E, Galimard JE, Kröger N, Blaise D, Peffault de Latour R, Kulagin A, Mousavi A, Stelljes M, Hamladji RM, Middeke JM, Salmenniemi U, Sengeloev H, Forcade E, Platzbecker U, Reményi P, Angelucci E, Chevallier P, Yakoub-Agha I, Craddock C, Ciceri F, Schroeder T, Aljurf M, Ch K, Moiseev I, Penack O, Schoemans H, Mohty M, Glass B, Sureda A, Basak G, Peric Z. Artificial intelligence methods to estimate overall mortality and non-relapse mortality following allogeneic HCT in the modern era: an EBMT-TCWP study. Bone Marrow Transplant 2024; 59:232-238. [PMID: 38007531 DOI: 10.1038/s41409-023-02147-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/25/2023] [Revised: 10/04/2023] [Accepted: 11/03/2023] [Indexed: 11/27/2023]
Abstract
Allogeneic haematopoietic cell transplantation (alloHCT) has curative potential counterbalanced by its toxicity. Prognostic scores fail to include current era patients and alternative donors. We examined adult patients from the EBMT registry who underwent alloHCT between 2010 and 2019 for oncohaematological disease. Our primary objective was to develop a new prognostic score for overall mortality (OM), with a secondary objective of predicting non-relapse mortality (NRM) using the OM score. AI techniques were employed. The model for OM was trained, optimized, and validated using 70%, 15%, and 15% of the data set, respectively. The top models, "gradient boosting" for OM (AUC = 0.64) and "elasticnet" for NRM (AUC = 0.62), were selected. The analysis included 33,927 patients. In the final prognostic model, patients with the lowest score had a 2-year OM and NRM of 18 and 13%, respectively, while those with the highest score had a 2-year OM and NRM of 82 and 93%, respectively. The results were consistent in the subset of the haploidentical cohort (n = 4386). Our score effectively stratifies the risk of OM and NRM in the current era but do not significantly improve mortality prediction. Future prognostic scores can benefit from identifying biological or dynamic markers post alloHCT.
Collapse
Affiliation(s)
- A Mussetti
- Department of Haematology, Institut Català d'Oncologia - Hospitalet, IDIBELL, University of Barcelona, Barcelona, Spain.
| | - B Rius-Sansalvador
- Biomarkers and Susceptibility Unit (UBS), Oncology Data Analytics Program (ODAP), Catalan Institute of Oncology (ICO), L'Hospitalet del Llobregat, Barcelona, Spain
- ONCOBELL Program, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain
| | - V Moreno
- Biomarkers and Susceptibility Unit (UBS), Oncology Data Analytics Program (ODAP), Catalan Institute of Oncology (ICO), L'Hospitalet del Llobregat, Barcelona, Spain
- ONCOBELL Program, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain
| | - C Peczynski
- EBMT Paris Study Office, Department of Haematology, Saint Antoine Hospital, INSERM Unité Mixte de Recherche (UMR)-S 938, Sorbonne University, Paris, France
| | - E Polge
- EBMT Global Committee (Shanghai and Paris Offices) and Acute Leukaemia Working Party, Hospital Saint-Antoine APHP and Sorbonne University, Paris, France
| | | | - N Kröger
- Department of Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - D Blaise
- Programme de Transplantation & Therapie Cellulaire, Centre de Recherche en Cancérologie de Marseille, Institut Paoli Calmettes, Marseille, France
| | - R Peffault de Latour
- Service d'Hématologie-Greffe, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris (APHP), Paris, France
- Université Paris Diderot, Institut Universitaire d'Hématologie, Sorbonne Paris Cité, Paris, France
| | - A Kulagin
- Raisa Memorial (RM) Gorbacheva Research Institute, Pavlov University, St. Petersburg, Russia
| | - A Mousavi
- Shariati Hospital, Haematology-Oncology and BMT Research, Tehran, Islamic Republic of Iran
| | - M Stelljes
- Department of Medicine A, University Hospital Münster, Münster, Germany
| | - R M Hamladji
- Centre Pierre et Marie Curie, Service Hématologie Greffe de Moëlle, Alger, Algeria
| | - J M Middeke
- Med. Klinik I, University Hospital, TU Dresden, Germany
| | - U Salmenniemi
- HUCH Comprehensive Cancer Center, Stem Cell Transplantation Unit, Helsinki, Finland
| | - H Sengeloev
- Bone Marrow Transplant Unit Copenhagen, Department of Haematology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
| | - E Forcade
- CHU Bordeaux, Service d'hématologie Clinique et Thérapie Cellulaire, 33000, Pessac, France
| | | | - P Reményi
- Department of Haematology and Stem Cell Transplant, Dél-pesti Centrumkórház - Országos Hematológiai és Infektológiai Intézet, Budapest, Hungary
| | - E Angelucci
- Haematology and Cellular Therapy Unit. IRCCS Ospedale Policlinico San Martino, Genova, Italy
| | | | - I Yakoub-Agha
- CHU de Lille LIRIC, INSERM U995, Université de Lille, Lille, France
| | - C Craddock
- Department of Haematology, University Hospital Birmingham NHS Trust, Queen Elizabeth Medical Centre, Edgbaston, Birmingham, UK
| | - F Ciceri
- Haematology & Bone Marrow Transplant, IRCCS San Raffaele Scientific Institute, Milan, Italy
| | - T Schroeder
- Department of Bone Marrow Transplantation, University Hospital, Essen, Germany
| | - M Aljurf
- Oncology Center, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia
| | | | - I Moiseev
- R.M.Gorbacheva Memorial Institute of Oncology, Haematology and Transplantation, Pavlov First Saint Petersburg State Medical University, Saint-Petersburg, Russian Federation
| | - O Penack
- Department of Haematology, Charité Universitätsmedizin Berlin, Berlin, Germany
| | - H Schoemans
- Department of Haematology, University Hospitals Leuven, Leuven, Belgium
- Department of Public Health and Primary Care, ACCENT VV, KU Leuven - University of Leuven, Leuven, Belgium
| | - M Mohty
- Department of Haematology, Saint Antoine Hospital, INSERM UMR 938, Sorbonne University, Paris, France
| | - B Glass
- Klinik für Hämatologie und Stammzelltransplantation, HELIOS Klinikum Berlin-Buch, Berlin, Germany
| | - A Sureda
- Department of Haematology, Institut Català d'Oncologia - Hospitalet, IDIBELL, University of Barcelona, Barcelona, Spain
| | - G Basak
- Department of Haematology, Transplantation and Internal Medicine, Medical University of Warsaw, Warsaw, Poland
| | - Z Peric
- School of medicine, University of Zagreb and University Hospital Centre Zagreb, Zagreb, Croatia
| |
Collapse
|
2
|
Potter V, Gras L, Koster L, Kroger N, Sockel K, Ganser A, Finke J, Labussiere-Wallet H, Peffault de Latour R, Koc Y, Salmenniemi U, Smidstrup Friis L, Jindra P, Schroeder T, Tischer J, Arat M, Pascual Cascon M, de Wreede LC, Hayden P, Raj K, Drozd-Sokolowska J, Scheid C, McLornan DP, Robin M, Yakoub-Agha I. Sequential vs myeloablative vs reduced intensity conditioning for patients with myelodysplastic syndromes with an excess of blasts at time of allogeneic haematopoietic cell transplantation: a retrospective study by the chronic malignancies working party of the EBMT. Bone Marrow Transplant 2024; 59:224-231. [PMID: 37993503 DOI: 10.1038/s41409-023-02111-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/19/2023] [Revised: 06/27/2023] [Accepted: 09/15/2023] [Indexed: 11/24/2023]
Abstract
The optimal conditioning for patients with higher risk MDS receiving potentially curative allogeneic haematopoietic stem cell transplant(allo-HCT) remains to be defined. This is particularly the case for patients with excess of blasts at time of allo-HCT. Sequential (Seq) conditioning, whereby chemotherapy is followed rapidly by transplant conditioning, offers an opportunity to decrease disease burden, potentially improving outcomes allo-HCT outcomes. Herein we present the only analysis comparing Seq to myeloablative (MAC) and reduced intensity conditioning (RIC) specifically focussed on MDS patients with excess of blasts at allo-HCT. 303 patients were identified in the EBMT registry, receiving RIC (n = 158), Seq (n = 105), and MAC (n = 40). Median follow-up was 67.2 months and median age at allo-HCT was 59.5 years (IQR 53.5-65.6). For the entire cohort, 3 y overall survival (OS) was 50% (95% CI 45-56%) and relapse free survival (RFS) 45% (95% CI 40-51%). No significant differences in OS (log-rank p = 0.13) and RFS (log-rank p = 0.18) were observed between conditioning protocols. On multivariable analysis, lower performance status, worse IPSS-R cytogenetics, sibling donor (compared to 8/8 MUD) and ≥20% blasts at allo-HCT were associated with worse outcomes. In conclusion, the Seq protocol did little to influence the outcome in this high-risk group of patients, with outcomes mostly determined by baseline disease risk and patient characteristics such as performance status.
Collapse
Affiliation(s)
- V Potter
- Kings College Hospital NHS Foundation Trust, London, UK.
| | - L Gras
- EBMT Statistical Unit, Leiden, Netherlands
| | - L Koster
- EBMT Leiden Study Unit, Leiden, Netherlands
| | - N Kroger
- University Hospital Eppendorf, Hamburg, Germany
| | - K Sockel
- Universitaetsklinikum Dresden, Dresden, Germany
| | - A Ganser
- Hannover Medical School, Hannover, Germany
| | - J Finke
- University of Freiburg, Freiburg, Germany
| | | | | | - Y Koc
- Medicana International Hospital Istanbul, Istanbul, Turkey
| | | | | | - P Jindra
- Charles University Hospital, Pilsen, Czech Republic
| | - T Schroeder
- University Hospital Essen, Dusseldorf, Germany
| | - J Tischer
- Klinikum Grosshadern, Munich, Germany
| | - M Arat
- Demiroglu Bilim University Istanbul Florence Nightingale Hospital, Stanbul, Turkey
| | | | - L C de Wreede
- Leiden University Medical Center, Dept of Biomedical Data Sciences, Leiden, Netherlands
| | - P Hayden
- Department of Haematology, Trinity College Dublin, St. James's Hospital, Dublin, Ireland
| | - K Raj
- University College London Hospitals NHS Trust, London, UK
| | | | - C Scheid
- University of Cologne, Cologne, Germany
| | - D P McLornan
- University College London Hospitals NHS Trust, London, UK
| | - M Robin
- Saint-Louis Hospital, BMT Unit, Paris, France
| | - I Yakoub-Agha
- CHU de Lille, Univ Lille, INSERM U1286, Infinite, 59000, Lille, France
| |
Collapse
|
3
|
André R, Ram-Wolff C, Battistella M, Peffault de Latour R, Petit A, Bouaziz JD, Brice P, Bagot M, De Masson A. Efficacité du brentuximab vedotin avant et après une allogreffe de cellules souches hématopoïétiques dans la prise en charge du mycosis fongoïde transformé. Ann Dermatol Venereol 2020. [DOI: 10.1016/j.annder.2020.09.402] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
4
|
Dangien A, Ram-Wolff C, Brice P, Battistella M, Roelens M, Moins-Teisserenc H, Peffault de Latour R, Mourah S, Bouaziz JD, Lebbé C, De Masson A, Bagot M. Traitement par ifosfamide et étoposide des lymphomes T cutanés primitifs avancés et réfractaires. Ann Dermatol Venereol 2020. [DOI: 10.1016/j.annder.2020.09.144] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
5
|
Del Galy AS, Marouf A, Raffoux E, Robin M, Michonneau D, Sébert M, Sicre de Fontebrune F, Xhaard A, Lengline E, Itzykson R, Frieri C, Dombret H, Fenaux P, Peffault de Latour R, Adès L, Socié G. Allogeneic hematopoietic stem cell transplantation in elderly patients with acute myeloid leukemia or myelodysplastic syndromes: myth and reality. Leukemia 2020; 35:225-228. [PMID: 32733010 DOI: 10.1038/s41375-020-1004-9] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/04/2020] [Revised: 07/16/2020] [Accepted: 07/22/2020] [Indexed: 11/09/2022]
Affiliation(s)
- A Sutra Del Galy
- Hematology-Transplantation, AP-HP Hospital St Louis, Paris, France.,University of Paris, Paris, France
| | - A Marouf
- Hematology-Transplantation, AP-HP Hospital St Louis, Paris, France
| | - E Raffoux
- Adult Hematology, AP-HP Hospital St Louis, Paris, France
| | - M Robin
- Hematology-Transplantation, AP-HP Hospital St Louis, Paris, France
| | - D Michonneau
- Hematology-Transplantation, AP-HP Hospital St Louis, Paris, France.,University of Paris, Paris, France.,INSERM UMR 976, Paris, France
| | - M Sébert
- Hematology Senior, AP-HP Hospital St Louis, Paris, France
| | | | - A Xhaard
- Hematology-Transplantation, AP-HP Hospital St Louis, Paris, France
| | - E Lengline
- Adult Hematology, AP-HP Hospital St Louis, Paris, France
| | - R Itzykson
- University of Paris, Paris, France.,Adult Hematology, AP-HP Hospital St Louis, Paris, France
| | - C Frieri
- Hematology-Transplantation, AP-HP Hospital St Louis, Paris, France.,University of Paris, Paris, France
| | - H Dombret
- University of Paris, Paris, France.,Adult Hematology, AP-HP Hospital St Louis, Paris, France
| | - P Fenaux
- University of Paris, Paris, France.,Hematology Senior, AP-HP Hospital St Louis, Paris, France
| | - R Peffault de Latour
- Hematology-Transplantation, AP-HP Hospital St Louis, Paris, France.,University of Paris, Paris, France
| | - L Adès
- University of Paris, Paris, France.,Hematology Senior, AP-HP Hospital St Louis, Paris, France
| | - G Socié
- Hematology-Transplantation, AP-HP Hospital St Louis, Paris, France. .,University of Paris, Paris, France. .,INSERM UMR 976, Paris, France.
| |
Collapse
|
6
|
Dangien A, Ram-Wolff C, Brice P, Battistella M, Roelens M, Moins-Teisserenc H, Peffault de Latour R, Mourah S, Bouaziz JD, Lebbé C, Bagot M, de Masson A. Ifosfamide and etoposide in advanced-stage, relapsed or refractory primary cutaneous T-cell lymphomas. Br J Dermatol 2020; 183:961-962. [PMID: 32407544 DOI: 10.1111/bjd.19220] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- A Dangien
- Dermatology, Saint-Louis Hospital, AP-HP, Paris, France
| | - C Ram-Wolff
- Dermatology, Saint-Louis Hospital, AP-HP, Paris, France
| | - P Brice
- Department of, Hematology, Saint-Louis Hospital, AP-HP, Paris, France
| | - M Battistella
- Department of, Pathology, Saint-Louis Hospital, AP-HP, Paris, France.,INSERM U976 Human Immunology, Pathophysiology and Immunotherapy, Paris, France.,Université de Paris, Paris, France
| | - M Roelens
- Université de Paris, Paris, France.,INSERM U1160, Paris, France
| | | | - R Peffault de Latour
- Department of, Hematology and Bone Marrow Transplant, Saint-Louis Hospital, AP-HP, Paris, France.,Université de Paris, Paris, France.,INSERM U1160, Paris, France
| | - S Mourah
- Department of Pharmacogenomics, Saint-Louis Hospital, AP-HP, Paris, France.,INSERM U976 Human Immunology, Pathophysiology and Immunotherapy, Paris, France.,Université de Paris, Paris, France
| | - J-D Bouaziz
- Dermatology, Saint-Louis Hospital, AP-HP, Paris, France.,INSERM U976 Human Immunology, Pathophysiology and Immunotherapy, Paris, France.,Université de Paris, Paris, France
| | - C Lebbé
- Dermatology, Saint-Louis Hospital, AP-HP, Paris, France.,INSERM U976 Human Immunology, Pathophysiology and Immunotherapy, Paris, France.,Université de Paris, Paris, France
| | - M Bagot
- Dermatology, Saint-Louis Hospital, AP-HP, Paris, France.,INSERM U976 Human Immunology, Pathophysiology and Immunotherapy, Paris, France.,Université de Paris, Paris, France
| | - A de Masson
- Dermatology, Saint-Louis Hospital, AP-HP, Paris, France.,INSERM U976 Human Immunology, Pathophysiology and Immunotherapy, Paris, France.,Université de Paris, Paris, France
| |
Collapse
|
7
|
Weiss M, de Masson A, Robin M, Peffault de Latour R, Bagot M, Socié G, Bouaziz JD. Complete remission of sclerodermatous cutaneous graft-versus-host disease after low-dose interleukine-2 treatment. J Eur Acad Dermatol Venereol 2020; 34:e791-e793. [PMID: 32329912 DOI: 10.1111/jdv.16524] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- M Weiss
- Dermatology Department, Université de Paris, Saint-Louis Hospital, Paris, France
| | - A de Masson
- Dermatology Department, Université de Paris, Saint-Louis Hospital, Paris, France
| | - M Robin
- Haematology Department, Université de Paris, Saint-Louis Hospital, Paris, France
| | - R Peffault de Latour
- Haematology Department, Université de Paris, Saint-Louis Hospital, Paris, France
| | - M Bagot
- Dermatology Department, Université de Paris, Saint-Louis Hospital, Paris, France
| | - G Socié
- Haematology Department, Université de Paris, Saint-Louis Hospital, Paris, France
| | - J-D Bouaziz
- Dermatology Department, Université de Paris, Saint-Louis Hospital, Paris, France
| |
Collapse
|
8
|
André R, Ram-Wolff C, Battistella M, Peffault de Latour R, Petit A, Bouaziz JD, Brice P, Bagot M, de Masson A. Effectiveness of brentuximab vedotin before and after allogeneic stem-cell transplantation in the management of transformed mycosis fungoides. Br J Dermatol 2020; 182:1503-1504. [PMID: 31854457 DOI: 10.1111/bjd.18806] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- R André
- Departments of Dermatology, Saint-Louis Hospital, AP-HP, Paris University, Inserm U976, Paris, France
| | - C Ram-Wolff
- Departments of Dermatology, Saint-Louis Hospital, AP-HP, Paris University, Inserm U976, Paris, France
| | - M Battistella
- Departments of Pathology, Saint-Louis Hospital, AP-HP, Paris University, Inserm U976, Paris, France
| | - R Peffault de Latour
- Departments of Hematology and Bone Marrow Transplantation, Saint-Louis Hospital, AP-HP, Paris University, Inserm U976, Paris, France
| | - A Petit
- Departments of Dermatology, Saint-Louis Hospital, AP-HP, Paris University, Inserm U976, Paris, France
| | - J D Bouaziz
- Departments of Dermatology, Saint-Louis Hospital, AP-HP, Paris University, Inserm U976, Paris, France
| | - P Brice
- Departments of Hematology and Bone Marrow Transplantation, Saint-Louis Hospital, AP-HP, Paris University, Inserm U976, Paris, France
| | - M Bagot
- Departments of Dermatology, Saint-Louis Hospital, AP-HP, Paris University, Inserm U976, Paris, France
| | - A de Masson
- Departments of Dermatology, Saint-Louis Hospital, AP-HP, Paris University, Inserm U976, Paris, France
| |
Collapse
|
9
|
Dumont M, Ram‐Wolff C, Roelens M, Brice P, Peffault de Latour R, Battistella M, Madelaine I, Delyon J, Herms F, Bouaziz J, Moins‐Teisserenc H, Lebbé C, Bagot M, Masson A. Efficacy and safety of brentuximab vedotin plus bendamustine in advanced‐stage primary cutaneous T‐cell lymphomas. Br J Dermatol 2019; 181:1315-1317. [DOI: 10.1111/bjd.18215] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Affiliation(s)
- M. Dumont
- Departments of Dermatology Saint‐Louis Hospital, AP‐HP, Paris 7 University 1 avenue Claude Vellefaux 75010 Paris France
| | - C. Ram‐Wolff
- Departments of Dermatology Saint‐Louis Hospital, AP‐HP, Paris 7 University 1 avenue Claude Vellefaux 75010 Paris France
| | - M. Roelens
- Immunology (Inserm U1160) Saint‐Louis Hospital, AP‐HP, Paris 7 University 1 avenue Claude Vellefaux 75010 Paris France
| | - P. Brice
- Hemato‐oncology Saint‐Louis Hospital, AP‐HP, Paris 7 University 1 avenue Claude Vellefaux 75010 Paris France
| | - R. Peffault de Latour
- Departments of Hematology‐Bone Marrow Transplantation Saint‐Louis Hospital, AP‐HP, Paris 7 University 1 avenue Claude Vellefaux 75010 Paris France
| | - M. Battistella
- Departments of Pathology (Inserm U976) Saint‐Louis Hospital, AP‐HP, Paris 7 University 1 avenue Claude Vellefaux 75010 Paris France
| | - I. Madelaine
- Pharmacy Saint‐Louis Hospital, AP‐HP, Paris 7 University 1 avenue Claude Vellefaux 75010 Paris France
| | - J. Delyon
- Departments of Dermatology Saint‐Louis Hospital, AP‐HP, Paris 7 University 1 avenue Claude Vellefaux 75010 Paris France
| | - F. Herms
- Departments of Dermatology Saint‐Louis Hospital, AP‐HP, Paris 7 University 1 avenue Claude Vellefaux 75010 Paris France
| | - J.‐D. Bouaziz
- Departments of Dermatology Saint‐Louis Hospital, AP‐HP, Paris 7 University 1 avenue Claude Vellefaux 75010 Paris France
| | - H. Moins‐Teisserenc
- Immunology (Inserm U1160) Saint‐Louis Hospital, AP‐HP, Paris 7 University 1 avenue Claude Vellefaux 75010 Paris France
| | - C. Lebbé
- Departments of Dermatology Saint‐Louis Hospital, AP‐HP, Paris 7 University 1 avenue Claude Vellefaux 75010 Paris France
| | - M. Bagot
- Departments of Dermatology Saint‐Louis Hospital, AP‐HP, Paris 7 University 1 avenue Claude Vellefaux 75010 Paris France
| | - A. Masson
- Departments of Dermatology Saint‐Louis Hospital, AP‐HP, Paris 7 University 1 avenue Claude Vellefaux 75010 Paris France
| |
Collapse
|
10
|
Röth A, Nagy Z, Peffault de Latour R, Ninomya H, Panse J, Yoon S, Egyed M, Ichikawa S, Ito Y, Seok Kim J, Schrezenmeier H, Sica S, Usuki K, Sostelly A, Higginson J, Dieckmann A, Anzures-Cabreras J, Shinomiya K, Klughammer B, Jahreis A, Bucher C, Nishimura J. PF348 LONG TERM FOLLOW-UP OF PNH PATIENTS TREATED WITH THE SMART ANTI-HC5 ANTIBODY (SKY59/RO7112689) IN THE OPEN LABEL EXTENSION (OLE) OF THE COMPOSER TRIAL. Hemasphere 2019. [DOI: 10.1097/01.hs9.0000559604.06488.14] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
11
|
Hurabielle C, Leboeuf C, Ram-Wolff C, Meignin V, Rivet J, Vignon-Pennamen MD, Bonnafous C, Sicard H, Fite C, Raffoux E, Arnulf B, Oksenhendler E, Sicre de Fontbrune F, Peffault de Latour R, Socié G, Bouaziz JD, Lebbé C, Bensussan A, Janin A, Bagot M, Battistella M. KIR3DL2 expression in patients with adult T-cell lymphoma/leukaemia. Br J Dermatol 2018; 179:197-199. [PMID: 29315492 DOI: 10.1111/bjd.16322] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Affiliation(s)
- C Hurabielle
- Service de Dermatologie, Hôpital Saint-Louis, AP-HP, Paris, France.,Inserm Unité 976, Hôpital Saint-Louis, AP-HP, Paris, France
| | - C Leboeuf
- Université Paris Diderot, INSERM UMRS1165, Paris, France
| | - C Ram-Wolff
- Service de Dermatologie, Hôpital Saint-Louis, AP-HP, Paris, France
| | - V Meignin
- Service D'Anatomo-Pathologie, Hôpital Saint-Louis, AP-HP, Paris, France
| | - J Rivet
- Service D'Anatomo-Pathologie, Hôpital Saint-Louis, AP-HP, Paris, France
| | | | | | - H Sicard
- Innate Pharma, Marseille, France
| | - C Fite
- Service de Dermatologie, Hôpital Bichat, AP-HP, Paris, France
| | - E Raffoux
- Service d'Hématologie, Hôpital Saint-Louis, AP-HP, Paris, France
| | - B Arnulf
- Service d'Immuno-Hématologie, Hôpital Saint-Louis, AP-HP, Paris, France
| | - E Oksenhendler
- Service d'Immuno-Hématologie, Hôpital Saint-Louis, AP-HP, Paris, France
| | | | | | - G Socié
- Service d'Hématologie-Greffe, Hôpital Saint-Louis, AP-HP, Paris, France
| | - J-D Bouaziz
- Service de Dermatologie, Hôpital Saint-Louis, AP-HP, Paris, France.,Inserm Unité 976, Hôpital Saint-Louis, AP-HP, Paris, France.,Université Paris Diderot, Sorbonne Paris Cité, Paris, France
| | - C Lebbé
- Service de Dermatologie, Hôpital Saint-Louis, AP-HP, Paris, France.,Inserm Unité 976, Hôpital Saint-Louis, AP-HP, Paris, France.,Université Paris Diderot, INSERM UMRS1165, Paris, France.,Université Paris Diderot, Sorbonne Paris Cité, Paris, France
| | - A Bensussan
- Inserm Unité 976, Hôpital Saint-Louis, AP-HP, Paris, France.,Université Paris Diderot, Sorbonne Paris Cité, Paris, France
| | - A Janin
- Université Paris Diderot, INSERM UMRS1165, Paris, France.,Service D'Anatomo-Pathologie, Hôpital Saint-Louis, AP-HP, Paris, France.,Université Paris Diderot, Sorbonne Paris Cité, Paris, France
| | - M Bagot
- Service de Dermatologie, Hôpital Saint-Louis, AP-HP, Paris, France.,Inserm Unité 976, Hôpital Saint-Louis, AP-HP, Paris, France.,Université Paris Diderot, Sorbonne Paris Cité, Paris, France
| | - M Battistella
- Université Paris Diderot, INSERM UMRS1165, Paris, France.,Service D'Anatomo-Pathologie, Hôpital Saint-Louis, AP-HP, Paris, France.,Université Paris Diderot, Sorbonne Paris Cité, Paris, France
| |
Collapse
|
12
|
Hurabielle C, Battistella M, Ram-Wolff C, Fite C, Meignin V, Rivet J, Vignon-Pennamen MD, de Risi-Pugliese T, Raffoux E, Arnulf B, Oksenhendler E, Sicre de Fontbrune F, Peffault de Latour R, Socié G, Bouaziz JD, Lebbé C, Bensussan A, Bagot M. Cutaneous presentation of adult T-cell leukemia/lymphoma (ATLL). Single-center study on 37 patients in metropolitan France between 1996 and 2016. Ann Dermatol Venereol 2018; 145:405-412. [PMID: 29661476 DOI: 10.1016/j.annder.2018.01.049] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/28/2017] [Revised: 08/31/2017] [Accepted: 01/15/2018] [Indexed: 12/01/2022]
Abstract
INTRODUCTION Adult T-cell leukemia/lymphoma (ATLL) is a hematological malignancy associated with chronic HTLV-1 infection. AIM To describe skin lesions in ATLL. METHODS A descriptive, retrospective study between 1996 and 2016, including all patients diagnosed with ATLL at Saint-Louis Hospital (Paris, France). RESULTS Thirty-seven ATLL patients were included. Fifteen patients (41%) had a cutaneous localization of the disease, which was present from the beginning of the disease for two thirds of them. ATLL types in patients with cutaneous localization of the disease were as follows: lymphoma, n=5, chronic, n=4, smoldering, n=4, acute, n=2. Half the patients had 2 or more cutaneous manifestations. The cutaneous localizations observed were as follows: nodulotumoral (n=8), plaques (n=7), multipapular (n=6), macular (n=4), purpuric (n=2). Among the 15 patients with cutaneous localization, median overall survival was significantly shorter in the acute and lymphoma types compared to the smoldering and chronic types (8.7 months vs. 79 months, P=0.003). DISCUSSION ATLL is a hematologic malignancy with variable expression that is diagnosed only very rarely in metropolitan France, but that should be sought in patients from countries with high HTLV-1 prevalence in the event of a chronic eruption with patches, papules, plaques and/or tumors. The chronic and smoldering types are relatively indolent, whereas the acute and lymphoma forms have a poor prognosis.
Collapse
Affiliation(s)
- C Hurabielle
- Dermatology department, hôpital Saint-Louis, AP-HP, 1, avenue Claude-Vellefaux, 75010 Paris, France; Inserm Unité 976, hôpital Saint-Louis, 1, avenue Claude-Vellefaux, 75010 Paris, France
| | - M Battistella
- Histopathology department, hôpital Saint-Louis, France Inserm Unit 976, AP-HP, 1, avenue Claude-Vellefaux, 75010 Paris, France; Université Paris-Diderot, Sorbonne-Paris-Cité, 75000 Paris, France.
| | - C Ram-Wolff
- Dermatology department, hôpital Saint-Louis, AP-HP, 1, avenue Claude-Vellefaux, 75010 Paris, France
| | - C Fite
- Dermatology department, hôpital Bichat, AP-HP, 46, rue Henri-Huchard, 75018 Paris, France
| | - V Meignin
- Histopathology department, hôpital Saint-Louis, France Inserm Unit 976, AP-HP, 1, avenue Claude-Vellefaux, 75010 Paris, France
| | - J Rivet
- Histopathology department, hôpital Saint-Louis, France Inserm Unit 976, AP-HP, 1, avenue Claude-Vellefaux, 75010 Paris, France
| | - M-D Vignon-Pennamen
- Histopathology department, hôpital Saint-Louis, France Inserm Unit 976, AP-HP, 1, avenue Claude-Vellefaux, 75010 Paris, France
| | - T de Risi-Pugliese
- Dermatology department, hôpital Saint-Louis, AP-HP, 1, avenue Claude-Vellefaux, 75010 Paris, France
| | - E Raffoux
- Haematology department, hôpital Saint-Louis, AP-HP, 1, avenue Claude-Vellefaux, 75010 Paris, France
| | - B Arnulf
- Immunology-Haematology department, hôpital Saint-Louis, AP-HP, 1, avenue Claude-Vellefaux, 75010 Paris, France
| | - E Oksenhendler
- Immunology-Haematology department, hôpital Saint-Louis, AP-HP, 1, avenue Claude-Vellefaux, 75010 Paris, France
| | - F Sicre de Fontbrune
- Haematology-transplantations department, hôpital Saint-Louis, AP-HP, 1, avenue Claude-Vellefaux, 75010 Paris, France
| | - R Peffault de Latour
- Haematology-transplantations department, hôpital Saint-Louis, AP-HP, 1, avenue Claude-Vellefaux, 75010 Paris, France
| | - G Socié
- Haematology-transplantations department, hôpital Saint-Louis, AP-HP, 1, avenue Claude-Vellefaux, 75010 Paris, France
| | - J-D Bouaziz
- Dermatology department, hôpital Saint-Louis, AP-HP, 1, avenue Claude-Vellefaux, 75010 Paris, France; Inserm Unité 976, hôpital Saint-Louis, 1, avenue Claude-Vellefaux, 75010 Paris, France; Université Paris-Diderot, Sorbonne-Paris-Cité, 75000 Paris, France
| | - C Lebbé
- Dermatology department, hôpital Saint-Louis, AP-HP, 1, avenue Claude-Vellefaux, 75010 Paris, France; Inserm Unité 976, hôpital Saint-Louis, 1, avenue Claude-Vellefaux, 75010 Paris, France; Université Paris-Diderot, Sorbonne-Paris-Cité, 75000 Paris, France
| | - A Bensussan
- Inserm Unité 976, hôpital Saint-Louis, 1, avenue Claude-Vellefaux, 75010 Paris, France; Université Paris-Diderot, Sorbonne-Paris-Cité, 75000 Paris, France
| | - M Bagot
- Dermatology department, hôpital Saint-Louis, AP-HP, 1, avenue Claude-Vellefaux, 75010 Paris, France; Inserm Unité 976, hôpital Saint-Louis, 1, avenue Claude-Vellefaux, 75010 Paris, France; Université Paris-Diderot, Sorbonne-Paris-Cité, 75000 Paris, France
| |
Collapse
|
13
|
Hurabielle C, Sicre de Fontbrune F, Moins-Teisserenc H, Robin M, Jachiet M, Coman T, Dhedin N, Cassius C, Chasset F, de Masson A, Michonneau D, Bagot M, Bergeron A, Socié G, Peffault de Latour R, Bouaziz JD. Efficacy and tolerance of ruxolitinib in refractory sclerodermatous chronic graft-versus-host disease. Br J Dermatol 2017; 177:e206-e208. [PMID: 28422274 DOI: 10.1111/bjd.15593] [Citation(s) in RCA: 21] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Affiliation(s)
- C Hurabielle
- Service de Dermatologie, AP-HP, Hôpital Saint-Louis, Paris, 75010, France
| | | | - H Moins-Teisserenc
- Service d'Immunobiologie, AP-HP, Hôpital Saint-Louis, Paris, 75010, France.,Université Paris Diderot-Paris VII, Sorbonne Paris Cité, Paris, France
| | - M Robin
- Service d'Hématologie, AP-HP, Hôpital Saint-Louis, Paris, 75010, France
| | - M Jachiet
- Service de Dermatologie, AP-HP, Hôpital Saint-Louis, Paris, 75010, France
| | - T Coman
- Service d'Hématologie, AP-HP, Hôpital Saint-Louis, Paris, 75010, France
| | - N Dhedin
- Service d'Hématologie, AP-HP, Hôpital Saint-Louis, Paris, 75010, France
| | - C Cassius
- Service de Dermatologie, AP-HP, Hôpital Saint-Louis, Paris, 75010, France
| | - F Chasset
- Service de Dermatologie, AP-HP, Hôpital Saint-Louis, Paris, 75010, France
| | - A de Masson
- Service de Dermatologie, AP-HP, Hôpital Saint-Louis, Paris, 75010, France
| | - D Michonneau
- Service d'Hématologie, AP-HP, Hôpital Saint-Louis, Paris, 75010, France
| | - M Bagot
- Service de Dermatologie, AP-HP, Hôpital Saint-Louis, Paris, 75010, France.,Université Paris Diderot-Paris VII, Sorbonne Paris Cité, Paris, France
| | - A Bergeron
- Université Paris Diderot-Paris VII, Sorbonne Paris Cité, Paris, France.,Service de Pneumologie, AP-HP, Hôpital Saint-Louis, Paris, 75010, France
| | - G Socié
- Service d'Hématologie, AP-HP, Hôpital Saint-Louis, Paris, 75010, France.,Université Paris Diderot-Paris VII, Sorbonne Paris Cité, Paris, France
| | - R Peffault de Latour
- Service d'Hématologie, AP-HP, Hôpital Saint-Louis, Paris, 75010, France.,Université Paris Diderot-Paris VII, Sorbonne Paris Cité, Paris, France
| | - J-D Bouaziz
- Service de Dermatologie, AP-HP, Hôpital Saint-Louis, Paris, 75010, France.,Université Paris Diderot-Paris VII, Sorbonne Paris Cité, Paris, France
| |
Collapse
|
14
|
Le Bourgeois A, Labopin M, Blaise D, Ceballos P, Vigouroux S, Peffault de Latour R, Marçais A, Bulabois C, Bay J, Chantepie S, Deconinck E, Daguindau E, Contentin N, Yakoub-Agha I, Cornillon J, Mercier M, Turlure P, Charbonnier A, Rorhlich P, N’Guyen S, Maillard N, Marchand T, Mohty M, Chevallier P. Reduced-intensity versus reduced-toxicity myeloablative fludarabine/busulfan-based conditioning regimens for allografted non-Hodgkin lymphoma adult patients: a retrospective study on behalf of the Société Francophone de Greffe de Moelle et de Thérapie Cellulaire. Ann Oncol 2017; 28:2191-2198. [DOI: 10.1093/annonc/mdx274] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022] Open
|
15
|
Roux C, Tifratene K, Socié G, Galambrun C, Bertrand Y, Rialland F, Jubert C, Pochon C, Paillard C, Sirvent A, Nelken B, Vannier JP, Freycon C, Beguin Y, Raus N, Yakoub-Agha I, Mohty M, Dalle JH, Michel G, Pradier C, Peffault de Latour R, Rohrlich PS. Outcome after failure of allogeneic hematopoietic stem cell transplantation in children with acute leukemia: a study by the société Francophone de greffe de moelle et de thérapie cellulaire (SFGM-TC). Bone Marrow Transplant 2017; 52:678-682. [DOI: 10.1038/bmt.2016.360] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/23/2016] [Revised: 11/30/2016] [Accepted: 12/06/2016] [Indexed: 01/11/2023]
|
16
|
Hurabielle C, Fontbrune FSD, Robin M, Moins-Teisserenc H, Coman T, Jachiet M, Cassius C, Chasset F, Bagot M, Peffault de Latour R, Socié G, Bouaziz JD. Efficacité et tolérance du ruxolitinib (JAKAVI) dans la GVH cutanée chronique sclérodermiforme cortico-résistante. Ann Dermatol Venereol 2016. [DOI: 10.1016/j.annder.2016.09.173] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
17
|
Roux D, Meyer G, Cymbalista F, Bouaziz JD, Falgarone G, Tesniere A, Gervais J, Cariou A, Peffault de Latour R, Marat M, Moenaert E, Guebli T, Rodriguez O, Lefort A, Dreyfuss D, Hajage D, Ricard JD. [Computerized ranking test in three French universities: Staff experience and students' feedback]. Rev Med Interne 2016; 37:166-72. [PMID: 26827272 DOI: 10.1016/j.revmed.2015.12.026] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/28/2015] [Revised: 11/26/2015] [Accepted: 12/29/2015] [Indexed: 10/22/2022]
Abstract
BACKGROUND The year 2016 will be pivotal for the evaluation of French medical students with the introduction of the first computerized National Ranking Test (ECNi). The SIDES, online electronic system for medical student evaluation, was created for this purpose. All the universities have already organized faculty exams but few a joint computerized ranking test at several universities simultaneously. We report our experience on the organization of a mock ECNi by universities Paris Descartes, Paris Diderot and Paris 13. METHODS Docimological, administrative and technical working groups were created to organize this ECNi. Students in their fifth year of medical studies, who will be the first students to sit for the official ECNi in 2016, were invited to attend this mock exam that represented more than 50% of what will be proposed in 2016. A final electronic questionnaire allowed a docimological and organizational evaluation by students. An analysis of ratings and rankings and their distribution on a 1000-point scale were performed. RESULTS Sixty-four percent of enrolled students (i.e., 654) attended the three half-day exams. No difference in total score and ranking between the three universities was observed. Students' feedback was extremely positive. Normalized over 1000 points, 99% of students were scored on 300 points only. Progressive clinical cases were the most discriminating test. CONCLUSION The organization of a mock ECNi involving multiple universities was a docimological and technical success but required an important administrative, technical and teaching investment.
Collapse
Affiliation(s)
- D Roux
- Université Paris Diderot, Sorbonne Paris Cité, 75205 Paris, France; Service de réanimation médicochirurgicale, hôpital Louis-Mourier, AP-HP, 178, rue des Renouillers, 92700 Colombes, France.
| | - G Meyer
- Université Paris Descartes, Sorbonne Paris Cité, 75006 Paris, France; Service de pneumologie, hôpital européen Georges-Pompidou, AP-HP, 75015 Paris, France
| | - F Cymbalista
- Université Paris 13, Sorbonne Paris Cité, 93000 Bobigny, France; Service d'hématologie biologique, hôpital Avicenne, AP-HP, 93000 Bobigny, France
| | - J-D Bouaziz
- Université Paris Diderot, Sorbonne Paris Cité, 75205 Paris, France; Service de dermatologie, hôpital Saint-Louis, AP-HP, 75010 Paris, France
| | - G Falgarone
- Université Paris 13, Sorbonne Paris Cité, 93000 Bobigny, France; Service de rhumatologie, hôpital Avicenne, AP-HP, 93000 Bobigny, France
| | - A Tesniere
- Université Paris Descartes, Sorbonne Paris Cité, 75006 Paris, France; Service de réanimation chirurgicale, hôpital Cochin, AP-HP, 74014 Paris, France
| | - J Gervais
- Université Paris Diderot, Sorbonne Paris Cité, 75205 Paris, France
| | - A Cariou
- Université Paris Descartes, Sorbonne Paris Cité, 75006 Paris, France; Service de réanimation médicale, hôpital Cochin, AP-HP, 74014 Paris, France
| | - R Peffault de Latour
- Université Paris Diderot, Sorbonne Paris Cité, 75205 Paris, France; Service d'hématologie greffe, hôpital Saint-Louis, AP-HP, 75010 Paris, France
| | - M Marat
- Université Paris Descartes, Sorbonne Paris Cité, 75006 Paris, France
| | - E Moenaert
- Université Paris Diderot, Sorbonne Paris Cité, 75205 Paris, France
| | - T Guebli
- Université Paris 13, Sorbonne Paris Cité, 93000 Bobigny, France
| | - O Rodriguez
- Université Paris Descartes, Sorbonne Paris Cité, 75006 Paris, France
| | - A Lefort
- Université Paris Diderot, Sorbonne Paris Cité, 75205 Paris, France; Service de médecine interne, hôpital Beaujon, AP-HP, 92110 Clichy, France
| | - D Dreyfuss
- Université Paris Diderot, Sorbonne Paris Cité, 75205 Paris, France; Service de réanimation médicochirurgicale, hôpital Louis-Mourier, AP-HP, 178, rue des Renouillers, 92700 Colombes, France
| | - D Hajage
- Université Paris Diderot, Sorbonne Paris Cité, 75205 Paris, France; Département d'épidémiologie et de recherche clinique, hôpital Louis-Mourier, AP-HP, 92700 Colombes, France
| | - J-D Ricard
- Université Paris Diderot, Sorbonne Paris Cité, 75205 Paris, France; Service de réanimation médicochirurgicale, hôpital Louis-Mourier, AP-HP, 178, rue des Renouillers, 92700 Colombes, France
| |
Collapse
|
18
|
Chantepie SP, Michallet M, Blaise D, Maury S, Deconinck E, Tabrizi R, Contentin N, Mohty M, Nguyen S, Lioure B, Raus N, Peffault de Latour R, Yakoub-Agha I, Reman O. Allogeneic stem cell transplantation (allo-SCT) for de novo Ph+ AML: a study from the French Society of Bone Marrow Transplantation and Cell Therapy. Bone Marrow Transplant 2015; 50:1586-8. [PMID: 26367219 DOI: 10.1038/bmt.2015.206] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- S P Chantepie
- Institut d'Hématologie de Basse-Normandie, Centre Hospitalier Universitaire, Côte de Nacre, Caen Cedex, France
| | - M Michallet
- Service d'hématologie, Centre Hospitalier Lyon Sud, Pierre-Bénite, France
| | - D Blaise
- Service d'hématologie, Institut Paoli-Calmettes, Marseille, France
| | - S Maury
- INSERM U 955, Hôpital Henri-Mondor, Créteil, France
| | - E Deconinck
- Service d'Hématologie, CHU Jean Minjoz, Besançon, France
| | - R Tabrizi
- Service d'Hématologie, Hôpital HAUT-LEVEQUE, CHU de Bordeaux, Pessac, France
| | - N Contentin
- Service d'Hématologie, Centre Henri Becquerel, Rouen, France
| | - M Mohty
- Hôpital Saint-Antoine, APHP, Paris, France.,Université Pierre & Marie Curie, Paris, France.,INSERM, UMRs 938, Paris, France
| | - S Nguyen
- Service d'Hématologie, Hopital Pitié-Salpétrière, Paris, France
| | - B Lioure
- Département d'Hématologie et Oncologie, Hôpital de Hautepierre, Strasbourg, France
| | - N Raus
- Service d'Hématologie, Hôpital Edouard Herriot, Lyon, France
| | | | - I Yakoub-Agha
- Greffe de moelle osseuse, Hôpital Huriez, Lille, France
| | - O Reman
- Institut d'Hématologie de Basse-Normandie, Centre Hospitalier Universitaire, Côte de Nacre, Caen Cedex, France
| | | |
Collapse
|
19
|
Peffault de Latour R, Labopin M, Cornelissen J, Vigouroux S, Craddock C, Blaise D, Huyn A, Vindelov L, Maertens J, Chevallier P, Fegueux N, Socié G, Cahn JY, Petersen E, Schouten H, Lioure B, Russell N, Corral LL, Ciceri F, Nagler A, Mohty M. In patients older than 55 years with AML in first CR, should we search for a matched unrelated donor when an old sibling donor is available? Bone Marrow Transplant 2015; 50:1411-5. [PMID: 26367237 DOI: 10.1038/bmt.2015.180] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/14/2015] [Revised: 07/05/2015] [Accepted: 07/08/2015] [Indexed: 01/08/2023]
Abstract
Allogeneic hematopoietic transplantation is increasingly used in patients aged 55 years or more with AML. The question of whether outcomes can be improved with an allele-level 8/8 HLA-matched unrelated donor (MUD) rather than an older HLA-matched sibling (MSD, more than 55 years) is still unanswered. We thus analyzed outcomes in 714 patients aged 55 years and older with AML in first CR (CR1) who received PBSCs after a reduced-intensity conditioning hematopoietic cell transplant from a MUD (n=310) or a MSD (n=404) in a recent period (2005-2010). The 3-year cumulative incidences (CIs) of non-relapse mortality were 17% and 23% with MSD and MUD, respectively (P=0.17). The 3-year CIs of relapse were 37% and 30%, respectively (P=0.12), resulting in a 3-year CI of leukemia-free survival of 46% and 47%, respectively (P=0.51). The 3-year overall survival was 49% with both MSD and MUD. In conclusion, HLA-identical sibling donors aged 55 years or more should not be excluded because of age for patients aged 55 years and older with AML in CR1.
Collapse
Affiliation(s)
- R Peffault de Latour
- Service d'Hématologie Greffe, AP-HP-Hôpital Saint Louis, Paris, France.,Paris Diderot University, EA 3518, Paris, France
| | - M Labopin
- ALWP-EBMT, AP-HP-Hôpital Saint Antoine, Paris, France.,Service d'Hématologie Clinique et de Thérapie Cellulaire, AP-HP-Hôpital Saint Antoine, Paris, France.,Universite Pierre et Marie Curie, Paris, France.,INSERM, UMRs 938, Paris, France
| | - J Cornelissen
- Hematology Department, Erasmus MC-Daniel den Hoed Cancer Centre, Rotterdam, The Netherlands
| | - S Vigouroux
- CHU Bordeaux-Hôpital Haut-levêque, Pessac, France
| | - C Craddock
- BMT unit, Centre for Clinical Haematology-Queen Elizabeth Hospital, Birmingham, UK
| | - D Blaise
- Institut Paoli Calmettes-Unité de Transplantation et de Thérapie Cellulaire-Inserm UMR 891, Marseille, France
| | - A Huyn
- Department of Hematology, Hopital de Purpan-CHU, Toulouse, France
| | - L Vindelov
- Bone Marrow Transplant Unit L 4043, Rigshospitalet, Copenhagen, Denmark
| | - J Maertens
- Department of Hematology, University Hospital Gasthuisberg, Leuven, Belgium
| | - P Chevallier
- Department of Hematology, Hopital Hotel Dieu-CHU, Nantes, France
| | - N Fegueux
- CHU Lapeyronie-Service d'Hématologie et Oncologie, Montpellier, France
| | - G Socié
- Service d'Hématologie Greffe, AP-HP-Hôpital Saint Louis, Paris, France.,Université Paris Diderot, Paris, France.,INSERM 1160, Paris, France
| | - J Y Cahn
- Department of Hematology, University Hospital, Grenoble, France.,University Medical Centre UMR 525 CNRS, Grenoble, France
| | - E Petersen
- Department of Hematology, Utrecht, The Netherlands
| | - H Schouten
- Department Internal Medicine Hematology/Oncology, University Hospital Maastricht, Maastricht, The Netherlands
| | - B Lioure
- Department of Onco-Hematologiy, CHU Hautepierre, Strasbourg, France
| | - N Russell
- Division of Hematology and BMT, Nottingham City Hospital, Nottingham, UK
| | - L L Corral
- Hospital Clínico-Servicio de Hematología, Salamanca, Spain
| | - F Ciceri
- Hematology and BMT Unit, EBMT CIC 813, San Raffaele Scientific Institute, Milano, Italy
| | - A Nagler
- ALWP-EBMT, AP-HP-Hôpital Saint Antoine, Paris, France.,Division of Hematology and Bone Marrow Transplantation, Chaim Sheba Medical Center, Tel-Hashomer, Israel
| | - M Mohty
- ALWP-EBMT, AP-HP-Hôpital Saint Antoine, Paris, France.,Service d'Hématologie Clinique et de Thérapie Cellulaire, AP-HP-Hôpital Saint Antoine, Paris, France.,Universite Pierre et Marie Curie, Paris, France.,INSERM, UMRs 938, Paris, France
| | | |
Collapse
|
20
|
Doutrelon C, Skopinski S, Boulon C, Constans J, Viallard JF, Peffault de Latour R. [Paroxysmal nocturnal hemoglobinuria: An unknown cause of thrombosis?]. ACTA ACUST UNITED AC 2015. [PMID: 26205796 DOI: 10.1016/j.jmv.2015.06.006] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
Abstract
Paroxysmal nocturnal hemoglobinuria (PNH) is a rare acquired disorder of hematopoietic stem cells. Somatic mutation in the phosphatidylinositol glycan class A (PIG-A), X-linked gene, is responsible for a deficiency in glycosphosphatidylinositol-anchored proteins (GPI-AP). The lack of one of the GPI-AP complement regulatory proteins (CD55, CD59) leads to hemolysis. The disease is diagnosed with hemolytic anemia, marrow failure and thrombosis. Thromboembolic complication occurs in 30% of patient after 10 years of follow-up and is the first event in one out of 10 patients. The two most common sites are hepatic and cerebral veins. These locations are correlated with high risk of death. Currently, these data are balanced with the use of a monoclonal antibody (Eculizumab), which has significantly improved the prognosis with a survival similar to general population after 36 months of follow-up. Anticoagulant treatment is recommended after a thromboembolic event but has no place in primary prophylaxis.
Collapse
Affiliation(s)
- C Doutrelon
- Service de médecine vasculaire, hôpital Saint-André, 1, rue Jean-Burguet, 33075 Bordeaux, France.
| | - S Skopinski
- Service de médecine vasculaire, hôpital Saint-André, 1, rue Jean-Burguet, 33075 Bordeaux, France
| | - C Boulon
- Service de médecine vasculaire, hôpital Saint-André, 1, rue Jean-Burguet, 33075 Bordeaux, France
| | - J Constans
- Service de médecine vasculaire, hôpital Saint-André, 1, rue Jean-Burguet, 33075 Bordeaux, France
| | - J-F Viallard
- Service de médecine interne et maladies infectieuses, hôpital Haut-Lévêque, avenue Magellan, 33600 Pessac, France
| | - R Peffault de Latour
- Service d'hématologie, hôpital Saint-Louis, 1, avenue Claude-Vellefaux, 75010 Paris, France
| |
Collapse
|
21
|
Chasset F, Le Buanec H, Sicre de Fontbrune F, de Masson A, Rivet J, Bergeron A, Frumholtz L, Schiavon V, Robin M, Rybojad M, Roux J, Tazi A, Peffault de Latour R, Bagot M, Socié G, Bensussan A, Bouaziz J. Présence de populations lymphocytaires Th1, Th17 et Tc17 dans la réaction du greffon contre l’hôte chronique (GVHc) psoriasiforme. Ann Dermatol Venereol 2015. [DOI: 10.1016/j.annder.2015.04.056] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
22
|
Robin M, Porcher R, Ades L, Raffoux E, Michallet M, François S, Cahn J, Delmer A, Wattel E, Vigouroux S, Bay J, Cornillon J, Huynh A, Nguyen S, Rubio M, Vincent L, Maillard N, Charbonnier A, de Latour RP, Oumedaly R, Dombret H, Fenaux P, Socié G. 15 HLA-MATCHED ALLOGENEIC STEM CELL TRANSPLANTATION IMPROVES OVERALL SURVIVAL OF HIGHER RISK MYELODYSPLASTIC SYNDROME. Leuk Res 2015. [DOI: 10.1016/s0145-2126(15)30016-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
23
|
Detrait MY, Morisset S, Peffault de Latour R, Yakoub-Agha I, Crocchiolo R, Tabrizi R, Bay JO, Chevalier P, Barraco F, Raus N, Vigouroux S, Magro L, Mohty M, Milpied N, Blaise D, Socié G, Michallet M. Pre-transplantation risk factors to develop sclerotic chronic GvHD after allogeneic HSCT: A multicenter retrospective study from the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC). Bone Marrow Transplant 2014; 50:253-8. [DOI: 10.1038/bmt.2014.244] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/22/2014] [Revised: 08/02/2014] [Accepted: 09/17/2014] [Indexed: 12/11/2022]
|
24
|
Cornillon J, Peffault de Latour R, Apaza S, Bourg MA, Courbon C, Evard S, Guiraud M, Le Bars L, Petit S, Magro L, Schmitt S, Tardieu L, Samsonova O, Tipton R, Yakoub-Agha I. Transfert de compétence : la mise en place d’un statut infirmier(ère) de greffe pour le suivi post-greffe : un rapport par la SFGM-TC. ACTA ACUST UNITED AC 2014; 62:190-2. [DOI: 10.1016/j.patbio.2014.05.003] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/22/2014] [Accepted: 05/14/2014] [Indexed: 11/17/2022]
|
25
|
Jachiet M, de Masson A, Peffault de Latour R, Rybojad M, Robin M, Bourhis JH, Xhaard A, Dhedin N, Sicre de Fontbrune F, Suarez F, Barete S, Parquet N, Nguyen S, Ades L, Rubio MT, Wittnebel S, Bagot M, Socié G, Bouaziz JD. Skin ulcers related to chronic graft-versus-host disease: clinical findings and associated morbidity. Br J Dermatol 2014; 171:63-8. [DOI: 10.1111/bjd.12828] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 01/06/2014] [Indexed: 11/29/2022]
Affiliation(s)
- M. Jachiet
- Department of Dermatology; AP-HP; Université Paris VII Sorbonne Paris Cité; and Hôpital Saint Louis; Paris France
| | - A. de Masson
- Department of Dermatology; AP-HP; Université Paris VII Sorbonne Paris Cité; and Hôpital Saint Louis; Paris France
| | - R. Peffault de Latour
- Department of Haematology; AP-HP; Université Paris VII Sorbonne Paris Cité; and Hôpital Saint Louis; Paris France
| | - M. Rybojad
- Department of Dermatology; AP-HP; Université Paris VII Sorbonne Paris Cité; and Hôpital Saint Louis; Paris France
| | - M. Robin
- Department of Haematology; AP-HP; Université Paris VII Sorbonne Paris Cité; and Hôpital Saint Louis; Paris France
| | - J.-H. Bourhis
- Department of Haematology; AP-HP; Institut Gustave Roussy; Villejuif France
| | - A. Xhaard
- Department of Haematology; AP-HP; Université Paris VII Sorbonne Paris Cité; and Hôpital Saint Louis; Paris France
| | - N. Dhedin
- Department of Haematology; AP-HP; Université Paris VII Sorbonne Paris Cité; and Hôpital Saint Louis; Paris France
| | - F. Sicre de Fontbrune
- Department of Haematology; AP-HP; Université Paris VII Sorbonne Paris Cité; and Hôpital Saint Louis; Paris France
| | - F. Suarez
- Department of Haematology; AP-HP; Hôpital Necker; Paris France
| | - S. Barete
- Department of Dermatology; AP-HP; Hôpital Pitié Salpêtrière; Paris France
| | - N. Parquet
- Department of Haematology; AP-HP; Université Paris VII Sorbonne Paris Cité; and Hôpital Saint Louis; Paris France
| | - S. Nguyen
- Department of Haematology; AP-HP; Hôpital Pitié Salpêtrière; Paris France
| | - L. Ades
- Departments of Haematology; AP-HP; Hôpital Avicenne; Bobigny France
| | - M.-T. Rubio
- Department of Haematology; AP-HP; Hôpital Saint Antoine; Paris France
| | - S. Wittnebel
- Department of Haematology; AP-HP; Institut Gustave Roussy; Villejuif France
| | - M. Bagot
- Department of Dermatology; AP-HP; Université Paris VII Sorbonne Paris Cité; and Hôpital Saint Louis; Paris France
| | - G. Socié
- Department of Haematology; AP-HP; Université Paris VII Sorbonne Paris Cité; and Hôpital Saint Louis; Paris France
| | - J.-D. Bouaziz
- Department of Dermatology; AP-HP; Université Paris VII Sorbonne Paris Cité; and Hôpital Saint Louis; Paris France
| |
Collapse
|
26
|
Ferry C, Saussine A, Bouaziz JD, Xhaard A, Peffault de Latour R, Ribaud P, Robin M, Cambau E, Socié G. Disseminated cutaneous infection due to Mycobacterium chelonae following hematopoietic stem cell transplantation. IDCases 2014; 1:68-9. [PMID: 26839776 PMCID: PMC4735022 DOI: 10.1016/j.idcr.2014.07.002] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/29/2014] [Accepted: 07/02/2014] [Indexed: 11/16/2022] Open
Abstract
This report describes two cases of disseminated cutaneous Mycobacterium chelonae after hematopoietic stem cell transplantation (HSCT).
Collapse
Affiliation(s)
- C Ferry
- Service hematologie greffe, AP-HP, Hôpital Saint-Louis, 1 avenue Claude Vellefaux, 75475 Paris Cedex 10, France
| | - A Saussine
- Service de dermatologie, AP-HP, Hôpital Saint-Louis, 1 avenue Claude Vellefaux, 75475 Paris Cedex 10, France
| | - J D Bouaziz
- Service de dermatologie, AP-HP, Hôpital Saint-Louis, 1 avenue Claude Vellefaux, 75475 Paris Cedex 10, France
| | - A Xhaard
- Service hematologie greffe, AP-HP, Hôpital Saint-Louis, 1 avenue Claude Vellefaux, 75475 Paris Cedex 10, France
| | - R Peffault de Latour
- Service hematologie greffe, AP-HP, Hôpital Saint-Louis, 1 avenue Claude Vellefaux, 75475 Paris Cedex 10, France
| | - P Ribaud
- Service hematologie greffe, AP-HP, Hôpital Saint-Louis, 1 avenue Claude Vellefaux, 75475 Paris Cedex 10, France
| | - M Robin
- Service hematologie greffe, AP-HP, Hôpital Saint-Louis, 1 avenue Claude Vellefaux, 75475 Paris Cedex 10, France
| | - E Cambau
- Department de bactériologie-virologie groupe hospitalier Lariboisière-Fernand Widal, Paris, France
| | - G Socié
- Service hematologie greffe, AP-HP, Hôpital Saint-Louis, 1 avenue Claude Vellefaux, 75475 Paris Cedex 10, France
| |
Collapse
|
27
|
De Masson A, Bouaziz JD, Peffault de Latour R, Benhamou Y, Moluçon-Chabrot C, Bay JO, Laquerrière A, Picquenot JM, Michonneau D, Leguy-Seguin V, Bonnotte B, Jardin F, Lévesque H, Socié G, Bagot M, Rybojad M. Fasciite de Shulman et aplasie médullaire idiopathique : description de quatre cas et revue de 19 cas de la littérature. Ann Dermatol Venereol 2013. [DOI: 10.1016/j.annder.2013.09.550] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
28
|
Jachiet M, de Masson A, Latour RPD, Bourhis JH, Robin M, Rybojad M, Xhaard A, Sicre de Fontbrune F, Suarez F, Barete S, Wittnebel S, Bagot M, Socié G, Bouaziz J. GVH cutanées chroniques ulcérées : spectre clinique et évolutif sur une cohorte rétrospective de 25 patients. Ann Dermatol Venereol 2013. [DOI: 10.1016/j.annder.2013.09.027] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
29
|
Bay JO, Peffault de Latour R, Bruno B, Coiteux V, Guillaume T, Hicheri Y, Paillard C, Suarez F, Turlure P, Alain S, Bulabois CE, Socié G, Bauters F, Yakoub-Agha I. [Diagnosis and treatment of CMV and EBV Reactivation as well as Post-transplant Lymphoproliferative Disorders following Allogeneic Stem Cell Transplantation: An SFGM-TC report]. ACTA ACUST UNITED AC 2013; 61:152-4. [PMID: 24011961 DOI: 10.1016/j.patbio.2013.07.003] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/17/2013] [Accepted: 07/18/2013] [Indexed: 10/26/2022]
Abstract
In the attempt to harmonize clinical practices between different French transplantation centers, the French Society of Bone Marrow Transplantation and Cell Therapy (SFGM-TC) set up the third annual series of workshops which brought together practitioners from all member centers and took place in October 2012 in Lille. Here the SFGM-TC addressed the issue of post-transplant CMV and EBV reactivation, and EBV-related Lymphoproliferative Disorders.
Collapse
Affiliation(s)
- J-O Bay
- Service de thérapie cellulaire et hématologie clinique, CHU Estaing, 1, place Lucie et Raymond Aubrac, 63003 Clermont-Ferrand cedex 1, France
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
30
|
Mialou V, Leblanc T, Peffault de Latour R, Dalle JH, Socié G. [Dyskeratosis congenita: an update]. Arch Pediatr 2013; 20:299-306. [PMID: 23352883 DOI: 10.1016/j.arcped.2012.12.003] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/11/2012] [Revised: 11/16/2012] [Accepted: 12/15/2012] [Indexed: 10/26/2022]
Abstract
Dyskeratosis congenita is a rare inherited bone marrow failure characterized by excessively short telomeres in highly proliferative tissues. These abnormalities are due to disturbance of the telomere maintenance machinery. The clinical presentation is characterized by skin pigmentation, nail dystrophy, and mucosal leukoplakia. All these mucocutaneous features are rare in childhood: they usually appear between 5 and 10 years of age. In young children, the initial presentation can associate bone marrow failure and neurological or ocular problems: Hoyeraal-Hreidarsson and Revesz syndromes, respectively. Clinical progression of the disease can lead to aplastic anemia (86% of all patients) and to pulmonary or hepatic complications. These patients also have an increased risk of cancer. Diagnosis is often suspected on bone marrow failure with no clinical or biological abnormalities compatible with Fanconi anemia diagnosis. The telomere length study can be helpful for diagnosis in case of aplastic anemia in children before studying gene mutations. Until now, 6 genes (DKC1, TERT, TERC, NOLA2, NOLA3, TINF2) have been identified in dyskeratosis congenita. Transmission of the disease can be autosomal recessive, autosomal dominant, or X-linked. In half of the cases, the genetic abnormality is unknown. Treatment of DC has to be adapted to each patient, from symptomatic or androgenic treatment to hematopoietic stem cell transplantation.
Collapse
Affiliation(s)
- V Mialou
- Institut d'hématologie et oncologie pédiatrique (IHOP), 1, place Professeur-J.-Renaut, 69008 Lyon, France.
| | | | | | | | | |
Collapse
|
31
|
Wang L, Romero M, Ratajczak P, Lebœuf C, Belhadj S, Peffault de Latour R, Zhao WL, Socié G, Janin A. Increased apoptosis is linked to severe acute GVHD in patients with Fanconi anemia. Bone Marrow Transplant 2012; 48:849-53. [PMID: 23222379 DOI: 10.1038/bmt.2012.237] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
Abstract
Fanconi anemia (FA) patients have an increased risk of acute GVHD (aGVHD) after hematopoietic SCT, with hypersensitivity to DNA-cross-linking agents and defective DNA repair. MicroRNA-34 and p53 can induce apoptosis after DNA damage.Here we assessed epithelial cell apoptosis, and studied TP53 and miR-34a expression in the skin and gut biopsies in five non-transplanted FA patients, in 20 FA patients with aGVHD and in 25 acquired aplastic anemia patients (AA). Epithelial apoptosis was higher in FA than in acquired AA patients in both the skin and gut biopsies, though they had a similar preparative regimen. Further study on gut biopsies in FA patients showed that this deleterious effect was not linked to TP53 gene overexpression. As, among p53-independent signaling pathways of apoptosis, the microRNA-34 family mimics p53 apoptotic effects in response to DNA damage, we studied miR-34a expression in the same series of FA patients' gut biopsies. MiR-34a expression level was higher in severe aGVHD compared with non-aGVHD subjects or non-transplanted patients, and significantly related to apoptotic cell numbers across the three groups of FA patients. Thus, in FA patients, increased apoptosis occurs in target epithelial cells of severe aGVHD, and this deleterious effect is linked to overexpression of miR-34a but not TP53.
Collapse
Affiliation(s)
- L Wang
- Inserm, U728, Paris, France
| | | | | | | | | | | | | | | | | |
Collapse
|
32
|
Bergeron A, Godet C, Chevret S, Lorillon G, Peffault de Latour R, de Revel T, Robin M, Ribaud P, Socié G, Tazi A. Bronchiolitis obliterans syndrome after allogeneic hematopoietic SCT: phenotypes and prognosis. Bone Marrow Transplant 2012. [PMID: 23208317 PMCID: PMC7091913 DOI: 10.1038/bmt.2012.241] [Citation(s) in RCA: 57] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
Abstract
Bronchiolitis obliterans syndrome (BOS) after allogeneic hematopoietic SCT (HSCT) is recognized as a new-onset obstructive lung defect (OLD) in pulmonary function testing and is related to pulmonary chronic GVHD. Little is known about the different phenotypes of patients with BOS and their outcomes. We reviewed the data of all allogeneic HSCT recipients referred to our pulmonary department for a non-infectious bronchial disease between 1999 and 2010. We identified 103 patients (BOS (n=77), asthma (n=11) and chronic bronchitis (n=15)). In patients with BOS, we identified two functional phenotypes: a typical OLD, that is, forced expiratory volume in 1 s (FEV1)/forced vital capacity (FVC) ratio <0.7 (n=53), and an atypical OLD with a concomitant decrease in the FEV1 <80% and FVC <80% predicted with a normal total lung capacity (n=24). The typical OLD was characterized by more severe FEV1 and fewer centrilobular nodules on the computed tomography scan. The FEV1 was not significantly affected during the follow-up, regardless of the phenotype. In addition to acute and extensive chronic GVHD, only the occurrence of BOS soon after transplantation and the intentional treatment of BOS with steroids were associated with a poor survival. The determination of patient subgroups should be explored to improve the management of this condition.
Collapse
Affiliation(s)
- A Bergeron
- Université Paris Diderot, Sorbonne Cité, Service de Pneumologie, AP-HP, Hôpital Saint Louis, Paris, France.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
33
|
Meppiel E, Crassard I, Peffault de Latour R, Socie G, Bousser MG. Cerebral Venous Thrombosis and Paroxysmal Nocturnal Hemoglobinuria: A Retrospective Study on Twelve Cases (P07.013). Neurology 2012. [DOI: 10.1212/wnl.78.1_meetingabstracts.p07.013] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
34
|
Xhaard A, Nahon P, Robin M, Baudry C, Ades L, Peffault de Latour R, Socié G. Hepatic GVHD leading to cirrhosis after allogeneic hematopoietic SCT. Bone Marrow Transplant 2012; 47:1484-5. [PMID: 22465975 DOI: 10.1038/bmt.2012.53] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/18/2023]
|
35
|
De Masson A, Bouaziz JD, Rybojad M, Peffault de Latour R, Robin M, Rodriguez-Otero P, Durant C, Socie G, Bagot M. EF/SSc overlap syndrome and aplastic anaemia resistant to immunosuppressive therapy. Rheumatology (Oxford) 2012; 51:762-4. [DOI: 10.1093/rheumatology/ker406] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
36
|
Quentin S, Cuccuini W, Ceccaldi R, Nibourel O, Pondarre C, Pages MP, de Latour RP, Rocha V, Michallet M, Schneider P, Michel G, Baruchel A, Sigaux F, Gluckman E, Leblanc T, Stoppa-Lyonnet D, Preudhomme C, Socie G, Soulier J. 260 Myelodysplasia and leukemia of Fanconi anemia are associated with a specific pattern of genomic abnormalities that includes RUNX1/AML1 lesions. Leuk Res 2011. [DOI: 10.1016/s0145-2126(11)70262-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
37
|
Ruggeri A, Peffault de Latour R, Carmagnat M, Clave E, Douay C, Larghero J, Cayuela JM, Traineau R, Robin M, Madureira A, Ribaud P, Ferry C, Devergie A, Purtill D, Rabian C, Gluckman E, Toubert A, Socié G, Rocha V. Outcomes, infections, and immune reconstitution after double cord blood transplantation in patients with high-risk hematological diseases. Transpl Infect Dis 2011; 13:456-65. [PMID: 21466640 DOI: 10.1111/j.1399-3062.2011.00632.x] [Citation(s) in RCA: 65] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
Double unrelated cord blood transplant (dUCBT) has been used to circumvent cell dose limitation of single UCBT; however, few data are available describing outcomes, infectious disease, and immune recovery. We analyzed 35 consecutive dUCBT recipients with high-risk malignant disorders (n=21) and bone marrow failure syndromes (n=14). Median follow-up was 32 months. Conditioning regimen was myeloablative in 14 and reduced intensity in 21 patients. Median infused nucleated cell dose was 4 × 10(7) /kg. Median time to absolute neutrophil count >0.5 × 10(9) /L was 25 days. Cumulative incidence (CI) of acute grade II-IV graft-versus-host disease was 47%. Estimated overall survival at 2 years was 48%. CI of first viral infections at 1 year was 92%. We observed 49 viral infections in 30 patients, 34 bacterial infections in 19 patients, and 16 fungal or parasitic infections in 12 patients. Lymphocyte subset analyses were performed at 3, 6, 9, and >12 months after dUCBT. Decreased T-cell and B-cell counts with expansion of natural killer cells were observed until 9 months post transplantation. Recovery of thymopoiesis measured by T-cell receptor excision circles was impaired until 9 months after dUCBT, when the appearance of new thymic precursors was observed. Delayed immune recovery and high incidence of infectious complications were observed after dUCBT in patients with high-risk hematological diseases.
Collapse
Affiliation(s)
- A Ruggeri
- Service d'Hématologie-Greffe, Hôpital Saint Louis, APHP, Paris University 7, Paris, France
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
38
|
Lissandre S, Bay JO, Cahn JY, Porcher R, Cacheux V, Cabrespine A, Cornillon J, Cassinat B, Peffault de Latour R, Socie G, Robin M. Retrospective study of allogeneic haematopoietic stem-cell transplantation for myelofibrosis. Bone Marrow Transplant 2010; 46:557-61. [DOI: 10.1038/bmt.2010.276] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
39
|
Peffault de Latour R, Amoura Z, Socié G. L’hémoglobinurie paroxystique nocturne. Rev Med Interne 2010; 31:200-7. [DOI: 10.1016/j.revmed.2008.12.020] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/06/2008] [Revised: 10/28/2008] [Accepted: 12/14/2008] [Indexed: 11/29/2022]
|
40
|
Ruggeri A, de Latour RP, Rocha V, Larghero J, Robin M, Rodrigues CA, Traineau R, Ribaud P, Ferry C, Devergie A, Gluckman E, Socié G. Double cord blood transplantation in patients with high risk bone marrow failure syndromes. Br J Haematol 2008; 143:404-8. [PMID: 18699847 DOI: 10.1111/j.1365-2141.2008.07364.x] [Citation(s) in RCA: 42] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
Patients with bone marrow failure syndromes (BMFS) who reject a first allogeneic transplant or fail immunosuppressive therapy (IST) have an especially grim prognosis. We report 14 patients (eight adults, six children) transplanted with double cord blood transplantation (dUCBT) for BMFS. Neutrophil recovery was observed in eight patients, with full donor chimerism of one unit, and acute GVHD in 10. With a median follow-up of 23 months, the estimated 2 years overall survival was 80 +/- 17% and 33 +/- 16% for patients with acquired and inherited BMFS, respectively. Transplantation of two partially HLA-matched UCB thus enables salvage treatment of high-risk patients with BMFS.
Collapse
Affiliation(s)
- A Ruggeri
- Service d'Hématologie-Greffe, Hôpital Saint Louis, APHP, Paris University 7, Paris, France
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
41
|
Kabbara N, Lacroix C, Peffault de Latour R, Socie G, Ghannoum M, Ribaud P. Breakthrough C. parapsilosis and C. guilliermondii blood stream infections in allogeneic hematopoietic stem cell transplant recipients receiving long-term caspofungin therapy. Haematologica 2008; 93:639-40. [DOI: 10.3324/haematol.11149] [Citation(s) in RCA: 50] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022] Open
|
42
|
Peffault de Latour R, Blin N, Socié G. Les complications à long terme des greffes chez l’adulte. ONCOLOGIE 2007. [DOI: 10.1007/s10269-007-0762-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
43
|
Vanneaux V, Foïs E, Robin M, Rea D, de Latour RP, Biscay N, Chantre E, Robert I, Wargnier A, Traineau R, Benbunan M, Marolleau JP, Socié G, Larghero J. Microbial contamination of BM products before and after processing: a report of incidence and immediate adverse events in 257 grafts. Cytotherapy 2007; 9:508-13. [PMID: 17786612 DOI: 10.1080/14653240701420427] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
BACKGROUND The incidence and potential clinical consequences of bacterial contamination of autologous and allogeneic BM products remains open to question. We report our experience of bacterial contamination of BM grafts and adverse events that occurred after transplantation. METHODS From January 2003 to February 2006, 257 BM harvests were processed and infused at our institution. Analysis of microbial contamination incidence before and after processing, sensitivity spectra of isolated bacteria and adverse events after graft infusion were analyzed. RESULTS Nineteen of 257 BM (7.4%) were contaminated. Coagulase-negative Staphylococcus (n=9) and Propionibacterium acnes (n=6) were the most frequently isolated microorganisms. Two of nine coagulase-negative staphylococci were found to be resistant to erythromycin and two of six P. acnes to fosfomycin and gentamycin. The frequency and severity of immediate adverse events reported in patients receiving a contaminated graft were similar to those observed in patients receiving a non-contaminated product. No major adverse sequelae occurred after infusion of contaminated grafts. Finally, none of the patients transplanted with a contaminated graft developed bacteriemia that could have been related to the isolated microorganism. DISCUSSION Microbial contamination of BM progenitor cell grafts does not induce severe clinical complications or infectious diseases after infusion. The vast majority of isolated pathogens were skin contaminants.
Collapse
Affiliation(s)
- V Vanneaux
- Unité de Thérapie Cellulaire, Hôpital Saint Louis, Assistance Publique-Hôpitaux de Paris, Paris, France
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
44
|
Peffault de Latour R, Asselah T, Lévy V, Scieux C, Devergie A, Ribaud P, Espérou H, Traineau R, Gluckman E, Valla D, Marcellin P, Socié G. Treatment of chronic hepatitis C virus in allogeneic bone marrow transplant recipients. Bone Marrow Transplant 2005; 36:709-13. [PMID: 16062173 DOI: 10.1038/sj.bmt.1705120] [Citation(s) in RCA: 41] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
We recently reported an increased incidence of cirrhosis in hepatitis C virus (HCV)-infected stem cell transplant (SCT) recipients. Here, we describe our experience in the treatment of these patients, which has been, to date, poorly reported in the literature. Among 99 HCV-infected HCT recipients, 36 had HCV-related liver lesions on biopsy requiring therapy. Owing to HCV treatment contraindications, only 61% of patients (22/36) could be treated. In all, 12 patients received more than one course of anti-HCV treatment if they had HCV RNA still detectable after the first course of treatment and no treatment contraindications. Combined therapy (pegylated interferon (IFN): n=9, or standard IFN: n=9, in combination with ribavirin) led to sustained virological response in 4/18 (20%) patients as compared to 2/20 (10%) in patients who received IFN alone. Hematological toxicity was more frequent with combined therapy. While anemia responded to erythropoietin and/or dose modification, thrombocytopenia usually led to treatment interruption (n=3). This study thus highlights the efficacy of combined therapy and emphasizes the fact that the undue safety concerns are not a problem when treating this particular population.
Collapse
Affiliation(s)
- R Peffault de Latour
- Service d'Hématologie - Greffe de Moelle Osseuse, et Université Paris VII, Hôpital Saint Louis, Paris Cedex, France
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
45
|
Chaoui D, Legrand O, Roche N, Cornet M, Lefebvre A, Peffault de Latour R, Sanhes L, Huchon G, Marie JP, Rabbat A. Incidence and prognostic value of respiratory events in acute leukemia. Leukemia 2004; 18:670-5. [PMID: 14762443 DOI: 10.1038/sj.leu.2403270] [Citation(s) in RCA: 82] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
Acute respiratory failure and infectious pneumonia are the major causes of death during induction chemotherapy of acute leukemia. However, the causes, incidence and prognostic value of all respiratory events (REs) occurring in this context have never been assessed prospectively. We recruited 65 consecutive patients with newly diagnosed acute leukemia into a 1-year prospective study (December 2000-November 2001) to evaluate the incidence and prognostic value of these events. REs were frequent: 38 were recorded in 30 patients. There was a significant relationship between REs and pre-existing respiratory disease and/or smoking. REs were caused by infection in 34% of cases, by an established cause other than infection in 42% and had an undetermined cause in 24%. Poor early outcome (death within 45 days of starting induction chemotherapy) in patients experiencing an RE was independently associated with a >25/min respiratory rate (P=0.003) and the nonachievement of complete remission (CR) (P<0.0001). Predictors of overall survival in the entire patient population were the absence of CR (P<0.0001), REs (P=0.02) and a > or =2 performance status (P=0.03). In conclusion, REs are frequent during induction chemotherapy of acute leukemia and represent an independent prognostic factor of poor outcome, regardless of their cause.
Collapse
Affiliation(s)
- D Chaoui
- Department of Hematology, Hôtel-Dieu, Paris, France
| | | | | | | | | | | | | | | | | | | |
Collapse
|